{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:15:43Z","timestamp":1794888943547,"version":"4.9.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare myeloid disorders that are challenging with regard to diagnosis and clinical management. To study the similarities and differences between these disorders, we undertook a multicenter international study of one of the largest case series (CNL, n\u00a0= 24; aCML, n\u00a0= 37 cases, respectively), focusing on the clinical and mutational profiles (n\u00a0= 53 with molecular data) of these diseases. We found no differences in clinical presentations or outcomes of both entities. As previously described, both CNL and aCML share a complex mutational profile with mutations in genes involved in epigenetic regulation, splicing, and signaling pathways. Apart from CSF3R, only EZH2 and TET2 were differentially mutated between them. The molecular profiles support the notion of CNL and aCML being a continuum of the same disease that may fit best within the myelodysplastic\/myeloproliferative neoplasms. We identified 4 high-risk mutated genes, specifically CEBPA (\u03b2\u00a0= 2.26, hazard ratio [HR]\u00a0= 9.54, P\u00a0= .003), EZH2 (\u03b2\u00a0= 1.12, HR\u00a0= 3.062, P\u00a0= .009), NRAS (\u03b2\u00a0= 1.29, HR\u00a0= 3.63, P\u00a0= .048), and U2AF1 (\u03b2\u00a0= 1.75, HR\u00a0= 5.74, P\u00a0= .013) using multivariate analysis. Our findings underscore the relevance of molecular-risk classification in CNL\/aCML as well as the importance of CSF3R mutations in these diseases.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008204","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T16:49:18Z","timestamp":1682527758000},"page":"1672-1681","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["CNL and aCML should be considered as a single entity based on molecular profiles and outcomes"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-5542","authenticated-orcid":false,"given":"Gonzalo","family":"Carre\u00f1o-Tarragona","sequence":"first","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"3Hematology Department, Guy\u2019s and St. Thomas NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-8195","authenticated-orcid":false,"given":"Jos\u00e9 Carlos","family":"Mart\u00ednez-\u00c1vila","sequence":"additional","affiliation":[{"name":"4Agricultural Economics, Statistics and Business Management Department, Escuela T\u00e9cnica Superior de Ingenier\u00eda Agr\u00f3nomica, Alimentaria y Biosistemas, Universidad Polit\u00e9cnica de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[{"name":"5Hematology Department, Hospital Cl\u00ednico, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-3243","authenticated-orcid":false,"given":"Francisca","family":"Ferrer-Mar\u00edn","sequence":"additional","affiliation":[{"name":"6Hematology Department, Hospital Morales Meseguer, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras, Universidad Cat\u00f3lica San Antonio de Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[{"name":"3Hematology Department, Guy\u2019s and St. Thomas NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Mora","sequence":"additional","affiliation":[{"name":"7Hematology Department, Hospital Universitario La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Francis","sequence":"additional","affiliation":[{"name":"8Hematology Department, Sheffield Hospital, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-4865","authenticated-orcid":false,"given":"Teresa","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"9Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Goddard","sequence":"additional","affiliation":[{"name":"10Hematology Department, Rotherham Hospital, Rotherham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-4404","authenticated-orcid":false,"given":"Manuel","family":"P\u00e9rez-Encinas","sequence":"additional","affiliation":[{"name":"11Hematology Department, Hospital Cl\u00ednico Universitario, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Narayanan","sequence":"additional","affiliation":[{"name":"12Hematology Department, University Hospital Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Raya","sequence":"additional","affiliation":[{"name":"13Hematology Department, Hospital Universitario de Canarias, Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Singh","sequence":"additional","affiliation":[{"name":"14The Clatterbridge Cancer Centre, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Toth","sequence":"additional","affiliation":[{"name":"15Hematology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Amat-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"5Hematology Department, Hospital Cl\u00ednico, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Mcilwaine","sequence":"additional","affiliation":[{"name":"16Hematology Department, Glasgow Royal Infirmary, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Alobaidi","sequence":"additional","affiliation":[{"name":"17Department of Haematology, Chelsea and Westminster NHS Trust West Middlesex Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-3641","authenticated-orcid":false,"given":"Karan","family":"Mayani","sequence":"additional","affiliation":[{"name":"18Hematology Department, Hospital General de La Palma, Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McGregor","sequence":"additional","affiliation":[{"name":"19Department of Haematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-2290","authenticated-orcid":false,"given":"Ruth","family":"Stuckey","sequence":"additional","affiliation":[{"name":"20Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-9663","authenticated-orcid":false,"given":"Bethan","family":"Psaila","sequence":"additional","affiliation":[{"name":"21MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"22Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Segura","sequence":"additional","affiliation":[{"name":"20Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-9802","authenticated-orcid":false,"given":"Caroline","family":"Alvares","sequence":"additional","affiliation":[{"name":"23Hematology Department, University Hospital of Wales, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Davidson","sequence":"additional","affiliation":[{"name":"24Hematology Department, Kirkcaldy Hospital, Fife, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Osorio","sequence":"additional","affiliation":[{"name":"25Hematology Department, Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cutting","sequence":"additional","affiliation":[{"name":"26Hematology Department, Doncaster Hospital, Doncaster, Yorkshire, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline P.","family":"Sweeney","sequence":"additional","affiliation":[{"name":"27Hematology Department, Vale of Leven Hospital, Alexandria, West Dunbartonshire, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rufi\u00e1n","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moreno","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cuenca","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Smith","sequence":"additional","affiliation":[{"name":"14The Clatterbridge Cancer Centre, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-8441","authenticated-orcid":false,"given":"Mar\u00eda Luz","family":"Morales","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Gil-Manso","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Koutsavlis","sequence":"additional","affiliation":[{"name":"28Hematology Department, Western General Hospital, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Wang","sequence":"additional","affiliation":[{"name":"29Haemato-Oncology Diagnostic Service, Liverpool Clinical Laboratories, Liverpool University Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-1002","authenticated-orcid":false,"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[{"name":"30Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rozman","sequence":"additional","affiliation":[{"name":"31Hemopathology Unit, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2555","authenticated-orcid":false,"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"32Wessex Regional Genetics Laboratory, Salisbury, United Kingdom"},{"name":"33Faculty of Medicine, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"20","key":"2023050514393289800_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2023050514393289800_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am J Hematol"},{"issue":"17","key":"2023050514393289800_bib3","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2023050514393289800_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2023050514393289800_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What\u2019s different about atypical CML and chronic neutrophilic leukemia?","volume":"2015","author":"Dao","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2023050514393289800_bib6","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: Implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2023050514393289800_bib7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023050514393289800_bib8","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2023050514393289800_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","article-title":"Genomics of chronic neutrophilic leukemia","volume":"129","author":"Maxson","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2023050514393289800_bib10","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2023050514393289800_bib11","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"10","key":"2023050514393289800_bib12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.19.00895","article-title":"Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"38","author":"Dao","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"2023050514393289800_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.blre.2018.07.004","article-title":"Current and evolving understanding of atypical chronic myeloid leukemia","volume":"33","author":"Schwartz","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"2023050514393289800_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"2023050514393289800_bib15","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"2023050514393289800_bib16","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1097\/HS9.0000000000000497","article-title":"Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia","volume":"4","author":"Fontana","year":"2020","journal-title":"Hemasphere"},{"issue":"16","key":"2023050514393289800_bib17","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023050514393289800_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12185-008-0128-x","article-title":"Bleeding tendency in chronic neutrophilic leukemia","volume":"88","author":"Shigekiyo","year":"2008","journal-title":"Int J Hematol"},{"issue":"9","key":"2023050514393289800_bib19","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","article-title":"Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"P\u00e9rez","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"2023050514393289800_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21186862","article-title":"Atypical chronic myeloid leukemia: where are we now?","volume":"21","author":"Cris\u00e0","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2023050514393289800_bib21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00277-016-2664-4","article-title":"Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia","volume":"95","author":"Stahl","year":"2016","journal-title":"Ann Hematol"},{"issue":"63","key":"2023050514393289800_bib22","doi-asserted-by":"crossref","first-page":"106948","DOI":"10.18632\/oncotarget.22157","article-title":"Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes","volume":"8","author":"Cedena","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"2023050514393289800_bib23","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.leukres.2008.04.024","article-title":"Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm","volume":"32","author":"Fend","year":"2008","journal-title":"Leuk Res"},{"issue":"24","key":"2023050514393289800_bib24","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2016-03-705053","article-title":"Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors","volume":"127","author":"Lavall\u00e9e","year":"2016","journal-title":"Blood"},{"issue":"20","key":"2023050514393289800_bib25","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/bloodadvances.2020002206","article-title":"Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features","volume":"4","author":"Calvo","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2023050514393289800_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"2","key":"2023050514393289800_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"7","key":"2023050514393289800_bib28","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023050514393289800_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023050514393289800_bib30","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2023050514393289800_bib31","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"2023050514393289800_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"10","key":"2023050514393289800_bib33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","article-title":"Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner","volume":"126","author":"Mochizuki-Kashio","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023050514393289800_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023050514393289800_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0171608","article-title":"Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis","volume":"12","author":"Shou","year":"2017","journal-title":"PLoS One"},{"key":"2023050514393289800_bib36","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.3324\/haematol.2017.163790","article-title":"Ruxolitinib, a potent JAK1\/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia","volume":"102","author":"Gunawan","year":"2017","journal-title":"Haematologica"},{"issue":"D","key":"2023050514393289800_bib37","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna","year":"2015","journal-title":"Cureus"},{"issue":"1","key":"2023050514393289800_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0774-4","article-title":"Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia","volume":"17","author":"Rocca","year":"2018","journal-title":"Mol Cancer"},{"issue":"4","key":"2023050514393289800_bib39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1672\/2048999\/blooda_adv-2022-008204-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1672\/2048999\/blooda_adv-2022-008204-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T14:40:17Z","timestamp":1683297617000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/9\/1672\/487101\/CNL-and-aCML-should-be-considered-as-a-single"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008204","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}